Výsledky vyhledávání - "L. Stelmah"

CASE SERIES OF NIVOLUMAB TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY HIV-RELATED LYMPHOMAS

Autor: A. Nekrasova, Sergey N. Bondarenko, M. Popova, Kirill V. Lepik, Ivan S. Moiseev, I. Tsygankov, N. Mikhaylova, Y. Rogacheva, V. Baykov, Boris V. Afanasyev, L. Stelmah

Publikováno v: Hematological Oncology. 37:500-502

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4c65a221e7ee040cb253b5d6ef9e58bd
https://doi.org/10.1002/hon.183_2631

Zobrazit plný text záznamu

892MO High-dose chemotherapy with autologous hematopoietic stem cell transplantation in patients with HIV-related lymphoma

Autor: V. Baykov, Y. Rogacheva, Y. Zalylov, N. Mikhaylova, L. Stelmah, Kirill V. Lepik, M. Popova, Sergey N. Bondarenko, I. Tsygankov

Publikováno v: Annals of Oncology. 31:S651

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f092ee31e63c120c4b7cd2d7c5a5b1b7
https://doi.org/10.1016/j.annonc.2020.08.010

Zobrazit plný text záznamu

Nivolumab treatment in patients with relapsed/refractory HIV-related lymphomas

Autor: Boris V. Afanasyev, L. Stelmah, A. Nekrasova, V. Baykov, M. Popova, I. Tsygankov, Sergey N. Bondarenko, Ivan S. Moiseev, N. Mikhaylova, Kirill V. Lepik, Y. Rogacheva

Publikováno v: Annals of Oncology. 29:x20-x21

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c104b98263f05950556c80cdaa0feb8d
https://doi.org/10.1093/annonc/mdy486.011

Zobrazit plný text záznamu

Influence of nivolumab on epidemiology of infectious complications in patients with relapse or refractory Hodgkin’s lymphoma

Autor: Y. Rogacheva, I. Barhatov, Ivan S. Moiseev, V. Baykov, A. Volkova, Y. Zalyalov, Kirill V. Lepik, Boris V. Afanasyev, N. Mikhailova, Nikolay Klimko, E. Kondakova, Sergey N. Bondarenko, M. Popova, I. Nikolaev, O. Goloshchapov, L. Stelmah

Publikováno v: Annals of Oncology. 30:xi23

Background The clinical development of checkpoint inhibitor-based immunotherapy has ushered in an exciting era of anticancer therapy. Despite many reports on anti PD-1 antibody therapy for the treatment of Hodgkin’s lymphoma (HL), the risk of infec

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::118045a7aa448b563594b38c67a55980
https://doi.org/10.1093/annonc/mdz449.017

Zobrazit plný text záznamu

INFECTIOUS COMPLICATIONS OF NIVOLUMAB THERAPY IN RELAPSED/REFRACTORY HODGKIN'S LYMPHOMA

Autor: E. Kondakova, M. Popova, Kirill V. Lepik, N. Mikhailova, O. Goloshchapov, Y. Rogacheva, Ivan S. Moiseev, Y. Zalyalov, V. Baykov, Sergey N. Bondarenko, I. Nikolaev, Nikolay Klimko, I. Barhatov, Boris V. Afanasyev, A. Volkova, L. Stelmah

Publikováno v: Hematological Oncology. 37:502-502

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::dbfef131c9f814b1c6a3b1513fbc3511
https://doi.org/10.1002/hon.184_2631

Zobrazit plný text záznamu